Skip to main content
Premium Trial:

Request an Annual Quote

GenePeeks Signs Up Alliance Global Group to Distribute Preconception Screen in Middle East, Africa

NEW YORK (GenomeWeb) – Preconception genetic testing firm GenePeeks said today that it has signed a distribution agreement with the Alliance Global Group (AGBL), which is based in Dubai in the United Arab Emirates.

Under the agreement, AGBL will offer GenePeeks' Preconception Screen to patients, healthcare providers, and laboratories in the Middle East and in Africa. AGBL will also introduce additional applications of GenePeeks' technology, which is called Virtual Progeny Analytics, through partnerships with centers of excellence in the region.

GenePeeks Co-Founder and CEO Anne Morriss said in a statement that AGBL is "another strong partner for our growing presence outside the US."

"GenePeeks' Preconception Screen is an important addition to our growing portfolio of genetic tests," said AGBL CEO Tamer Degheidy in the announcement.

GenePeeks uses genomic data from prospective parents to predict the genetic disease risk of hypothetical children, applying a proprietary Variant Gene Dysfunction score. The firm says that unlike traditional carrier screening tests, it "focuses on a future child's true risk of disease inheritance." The Cambridge, Massachusetts-based company offers the test as a physician-ordered service through its CLIA laboratory.

In 2016, GenePeeks raised $16 million in a Series B funding round that was led by 5AM Ventures. Columbus Nova Technology Partners, Alexandria Venture Investments, Alta Partners, and several individual investors also participated in the round.

The Alliance Global Group is focused on bringing new technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets of the Middle East, Africa, and Asia.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.